Skip to main content
Journal cover image

Estimating the real-world performance of the PROMISE minimal-risk tool.

Publication ,  Journal Article
Nanna, MG; Wang, TY; Chiswell, K; Sun, JL; Vemulapalli, S; Hoffmann, U; Patel, MR; Udelson, JE; Fordyce, CB; Douglas, PS
Published in: Am Heart J
September 2021

BACKGROUND: Stable chest pain is a common indication for cardiac catheterization. We assessed the prognostic value of the Prospective Multicenter Imaging Study for Evaluation (PROMISE) Minimal-Risk Tool in identifying patients who are at very low risk of obstructive coronary artery disease (CAD) or downstream cardiovascular adverse outcomes. METHODS: We applied the PROMISE Minimal-Risk Tool to consecutive patients without known CAD who underwent elective cardiac catheterization for stable angina from January 1, 2000 to December 31, 2014 in the Duke Databank for Cardiovascular Disease (DDCD). Patients with scores >0.46 (top decile of lowest-risk from the PROMISE cohort) were classified as low-risk. Logistic regression modeling compared likelihood of freedom from obstructive coronary artery disease on index angiography, 2-year survival, and 2-year survival free of myocardial infarction (MI) and MI/revascularization between low- and non low-risk patients. Alternative cut points to define low- risk patients were also explored. RESULTS: Among 6251 patients undergoing cardiac catheterization for stable chest pain, 1082 (17.3%) were low-risk per the PROMISE minimal-risk tool. Among low risk patients, obstructive coronary artery disease was observed in 14.9% and left main disease (≥ 50% Stenosis) was rare (0.9%). Compared with other patients, low risk patients had a higher likelihood of freedom from obstructive coronary disease on index catheterization (85.1% vs. 44.2%, OR 4.84, 95% CI 4.06-5.77). Low risk patients had significantly higher survival (98.2% vs. 94.4%, OR 3.18, 95% CI 1.99-5.08), MI-free survival (97.2% vs. 91.9%, OR 3.03, 95% CI 2.07-4.45), and MI/revascularization-free survival (86.2 vs. 59.9%, OR 4.19, 95% CI 3.48-5.05) at 2 years than non-low risk patients. Operating characteristics for predicting the outcomes of interest varied modestly depending on the low-risk cut-point used but the positive predictive value for 2 year freedom from death was >98% regardless. CONCLUSION: The PROMISE minimal-risk tool identifies 17% of stable chest pain patients referred to cardiac catheterization as low risk. These patients have a low prevalence of obstructive CAD and better survival than non-low risk patients. While this suggests that these patients are unlikely to benefit from catheterization, further research is needed to confirm a favorable downstream prognosis with medical management alone.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

September 2021

Volume

239

Start / End Page

100 / 109

Location

United States

Related Subject Headings

  • United States
  • Risk Assessment
  • Prognosis
  • Outcome and Process Assessment, Health Care
  • Myocardial Revascularization
  • Myocardial Infarction
  • Middle Aged
  • Medical Overuse
  • Male
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Nanna, M. G., Wang, T. Y., Chiswell, K., Sun, J. L., Vemulapalli, S., Hoffmann, U., … Douglas, P. S. (2021). Estimating the real-world performance of the PROMISE minimal-risk tool. Am Heart J, 239, 100–109. https://doi.org/10.1016/j.ahj.2021.05.016
Nanna, M. G., T. Y. Wang, K. Chiswell, J. L. Sun, S. Vemulapalli, U. Hoffmann, M. R. Patel, J. E. Udelson, C. B. Fordyce, and P. S. Douglas. “Estimating the real-world performance of the PROMISE minimal-risk tool.Am Heart J 239 (September 2021): 100–109. https://doi.org/10.1016/j.ahj.2021.05.016.
Nanna MG, Wang TY, Chiswell K, Sun JL, Vemulapalli S, Hoffmann U, et al. Estimating the real-world performance of the PROMISE minimal-risk tool. Am Heart J. 2021 Sep;239:100–9.
Nanna, M. G., et al. “Estimating the real-world performance of the PROMISE minimal-risk tool.Am Heart J, vol. 239, Sept. 2021, pp. 100–09. Pubmed, doi:10.1016/j.ahj.2021.05.016.
Nanna MG, Wang TY, Chiswell K, Sun JL, Vemulapalli S, Hoffmann U, Patel MR, Udelson JE, Fordyce CB, Douglas PS. Estimating the real-world performance of the PROMISE minimal-risk tool. Am Heart J. 2021 Sep;239:100–109.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

September 2021

Volume

239

Start / End Page

100 / 109

Location

United States

Related Subject Headings

  • United States
  • Risk Assessment
  • Prognosis
  • Outcome and Process Assessment, Health Care
  • Myocardial Revascularization
  • Myocardial Infarction
  • Middle Aged
  • Medical Overuse
  • Male
  • Humans